Key result
Cardiac magnetic resonance imaging is a valuable tool for the diagnosis and follow-up of cardiotoxicity associated with various antitumor therapies, providing multiparametric tissue characterization.
Why the study?
Practicing cardiologists need information regarding the manifestations of cardiotoxicity in patients on or after antitumor therapy and the potential role of CMR in their diagnosis and follow-up.
CMR is a valuable multiparametric imaging modality for the early diagnosis and follow-up of cancer therapy-related cardiac dysfunction, offering advantages in tissue characterization and right heart assessment.
CMR may aid early cardiotoxicity monitoring; hypothesis-generating and should not change practice without prospective validation.
The purpose of this review article is to inform practicing cardiologists about the manifestations of cardiotoxicity in patients on or after antitumor therapy and about the potential of cardiac magnetic resonance imaging (CMR) in the diagnosis and follow-up of these patients. The definitions and classification of cardiotoxicity associated with antitumor treatment, the mechanisms of cardiac and vascular damage of some of the important groups of antitumor drugs, and the potential CMR findings are reviewed. The main clinical situations related to manifestations of cardiotoxicity in which CMR has or is expected to have a leading role are outlined.
No takes yet. Share an insight, caveat, or question.
Petkov et al. (2022) conducted a review in Cardiotoxicity associated with antitumor treatment. Cardiac magnetic resonance imaging (CMR) was evaluated. Cardiac magnetic resonance imaging is a valuable tool for the diagnosis and follow-up of cardiotoxicity associated with various antitumor therapies, providing multiparametric tissue characterization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: